Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes

<div>Frequency of responder subjects at 30% and 50% of 25 diabetic patients with chronic pain consequent on peripheral arteriopathy disease with tapentadol PR for 3 months.</div>

Journal of Diabetes Research

fig2

Figure 2

Figure 2: Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes 